Loading...
Loading...
Pneumonic plague is the most severe and rapidly fatal form of plague caused by Yersinia pestis, with mortality rates approaching 100% if untreated and over 50% even with appropriate antimicrobial therapy. [1] This highly contagious form requires immediate recognition and aggressive treatment.
• Onset and progression of fever, cough, and dyspnea (typically 1-6 days, most often 2-4 days after exposure) [2]
• Hemoptysis - bloody, watery, or purulent sputum production [2]
• Chest pain (pleuritic) and dyspnea severity [3]
• Gastrointestinal symptoms: nausea, vomiting, abdominal pain, diarrhea [2]
• Recent travel to endemic areas (western US, Madagascar, Democratic Republic of Congo) [4]
• Animal exposure history (rodents, cats, marmots, prairie dogs) [5]
• Contact with sick individuals or attendance at funerals [6]
• Incubation period: few hours to 2-3 days [3]
• Rapid progression to respiratory failure within 2-6 days [2]
• Sudden onset with high fever [3]
• Absence of buboes (except rarely cervical) distinguishes primary from secondary pneumonic plague [2]
• Hemoptysis - unique feature distinguishing from ordinary pneumonia [7]
• Rapid progression to respiratory failure within 24-48 hours [5][7]
• High fever with severe dyspnea and cough [3]
• Altered mental status, coma [5]
• Prominent gastrointestinal symptoms with respiratory illness [2]
• Signs of sepsis and multiorgan failure [2]
• Coagulation abnormalities and bleeding [2]
• Bilateral pulmonary infiltrates [2]
• Death can occur within 48 hours of symptom onset [5]
• Penicillin - associated with 75% case fatality rate [8]
• Beta-lactam antibiotics less effective than aminoglycosides or quinolones [3]
• Delay in antibiotic treatment beyond 24 hours significantly increases mortality [2]
• Dual therapy recommended for severe cases and bioterrorism scenarios [9]
• NPO if severe illness or intubated
• Maintain hydration and electrolyte balance
• Nutritional support as tolerated during recovery
• Constitutional: fever, chills, malaise, headache [9]
• Respiratory: cough, hemoptysis, chest pain, dyspnea [3]
• Gastrointestinal: nausea, vomiting, abdominal pain, diarrhea [2]
• Neurologic: altered mental status, agitation, prostration [3]
• Skin: petechial bleeding, purpura (late findings) [2]
• Recent deaths in household or community [6]
• Attendance at funerals or care of sick individuals [6]
• Travel companions with similar illness
• Occupational exposure (veterinarians, hunters) [1]
• No specific hereditary predisposition
• Household contacts at high risk for transmission [9]
• Geographic exposure: endemic areas (western US, Madagascar, DRC) [4]
• Animal contact: rodents, cats, marmots, prairie dogs [5]
• Occupational: hunters, veterinarians, laboratory workers [1]
• Poverty: increased rodent exposure [1]
• Close contact with pneumonic plague patients (<6 feet) [9]
• Children equally susceptible but not at higher risk for complications [9]
• Pregnant women: risk of hemorrhage, fetal demise, preterm birth [9]
• Community-acquired pneumonia (S. pneumoniae, H. influenzae, S. aureus)
• Atypical pneumonia (Mycoplasma, Legionella, Chlamydia)
• Viral pneumonia with bacterial superinfection
• Hantavirus pulmonary syndrome (if rodent exposure)
• Tularemia (if animal exposure)
• Bioterrorism-related pneumonic plague [9]
• Severe acute respiratory syndrome (SARS)
• Anthrax pneumonia
• Melioidosis
• Hemoptysis more prominent in plague [7]
• Rapid progression and high mortality [1]
• Gastrointestinal symptoms common in plague [2]
• Geographic and exposure history crucial [4]
• Previous plague episodes (rare)
• Immunocompromising conditions
• Chronic respiratory disease
• Recent antibiotic use affecting culture results [1]
• Vital signs: high fever, tachypnea, tachycardia, hypotension [2]
• Pulmonary: bilateral rales, consolidation, decreased breath sounds [2]
• Lymph nodes: cervical lymphadenopathy (rare in primary pneumonic) [2]
• Skin: petechiae, purpura (late findings) [2]
• Neurologic: altered mental status, agitation [3]
• Absence of buboes expected in primary pneumonic plague [2]
• Signs of sepsis and shock indicate severe disease [2]
• Complete blood count: leukocytosis with toxic granulations [2]
• Comprehensive metabolic panel: aminotransferase elevations, azotemia [2]
• Coagulation studies: PT/PTT, fibrinogen, D-dimer [2]
• Blood cultures (usually positive) [3]
• Sputum culture and Gram stain [2]
• Leukocytosis with left shift [2]
• Elevated liver enzymes [2]
• Coagulation abnormalities [2]
• Evidence of multiorgan failure [2]
• F1 antigen rapid dipstick test (if available in endemic areas) [6]
• PCR for pla gene (reference laboratory) [3]
• Wright-Giemsa or Wayson stain showing bipolar staining [2]
• Chest X-ray: bilateral infiltrates or consolidation common [2]
• Variable patterns: lobar consolidation, nodular infiltrates, pleural effusion [9]
• Multiple nodules in central lung regions [5]
• Consolidation in secondary pulmonary lobules [5]
• Gravity-dependent distribution pattern [5]
• Findings consistent with pulmonary hemorrhage and diffuse alveolar damage [5]
• Should not delay antibiotic treatment [2]
• F1 antigen dipstick test (rapid, field-deployable) [6]
• Direct fluorescent antibody testing [2]
• Bacteriophage lysis test for confirmation [3]
• F1 rapid diagnostic test (70% specificity for pneumonic plague) [1]
• Not routinely indicated unless cardiac complications suspected
• May show tachycardia, signs of strain from sepsis
• Monitor for arrhythmias in severe sepsis
• Pneumonic plague is a medical emergency requiring immediate antibiotic therapy [1]
• Case fatality rate: 25-50% even with treatment [1][4]
• Rapid progression from symptom onset to death (2-6 days historically) [2]
• Severe: respiratory failure, sepsis, multiorgan dysfunction [2]
• Moderate: stable vital signs but pneumonic symptoms
• Complications: ARDS, DIC, shock, multiorgan failure [2]
• Immediate isolation with droplet precautions [7]
• Aggressive supportive care for sepsis and respiratory failure [3]
• Empirical antibiotics - do not delay for confirmatory testing [2]
First-line antibiotics (10-14 days): [9]
• Ciprofloxacin: 400 mg IV q8h or 750 mg PO q12h
• Levofloxacin: 750 mg IV/PO daily
• Gentamicin: 5 mg/kg IV daily
• Streptomycin: 1 g IM/IV q12h
Alternative antibiotics: [9]
• Doxycycline: 200 mg loading dose, then 100 mg q12h
• Chloramphenicol: 12.5-25 mg/kg IV q6h (max 1 g/dose)
Dual therapy recommended for: [9]
• Severe pneumonic or septicemic plague
• Suspected bioterrorism cases
• Use two distinct antibiotic classes until sensitivities known
• All suspected pneumonic plague cases require hospitalization [4]
• ICU admission for respiratory failure, sepsis, or multiorgan dysfunction
• Isolation with droplet precautions for minimum 48 hours of effective treatment [9]
• Clinical improvement with decreased sputum production [9]
• Completed 48 hours of effective antimicrobial therapy [9]
• Stable vital signs and adequate oral intake
• Infectious disease consultation recommended
• Pulmonology if respiratory failure
• Public health notification mandatory [10]
• Daily monitoring during first 3 days of treatment [4]
• Weekly follow-up until treatment completion
• Contact tracing and prophylaxis coordination [10]
• Worsening respiratory symptoms despite treatment
• New fever or clinical deterioration
• Signs of treatment failure or complications
• Droplet precautions until 48 hours of effective treatment [9]
• Contact identification for prophylaxis [9]
• Medication compliance critical for survival
• Expected recovery course: gradual improvement over 7-14 days with appropriate treatment
• Immediate reporting to local health department [10]
• Contact tracing and postexposure prophylaxis [9]
• Infection control measures in healthcare settings [9]
1. Rapid Diagnostic Tests for Plague. — Jullien S, Dissanayake HA, Chaplin M. The Cochrane Database of Systematic Reviews. 2020.
2. Plague as a Biological Weapon: Medical and Public Health Management. — Inglesby TV, Dennis DT, Henderson DA, et al. The Journal of the American Medical Association. 2000.
3. Plague. — Prentice MB, Rahalison L. Lancet. 2007.
4. Ciprofloxacin versus Aminoglycoside–Ciprofloxacin for Bubonic Plague. — Randremanana RV, Raberahona M, Bourner J, et al. The New England Journal of Medicine. 2025.
5. Imaging Analysis of Pneumonic Plague Infection in Xizang, China: A Case Report and Literature Review. — Wang W, Li X, Wu J, Fu X, Li B. BMC Pulmonary Medicine. 2024.
6. Epidemiological and Diagnostic Aspects of the Outbreak of Pneumonic Plague in Madagascar. — Ratsitorahina M, Chanteau S, Rahalison L, Ratsifasoamanana L, Boisier P. Lancet. 2000.
7. Clinical Management of Potential Bioterrorism-Related Conditions. — Adalja AA, Toner E, Inglesby TV. The New England Journal of Medicine. 2015.
8. Treatment of Human Plague: A Systematic Review of Published Aggregate Data on Antimicrobial Efficacy, 1939-2019. — Godfred-Cato S, Cooley KM, Fleck-Derderian S, et al. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 2020.
9. Antimicrobial Treatment and Prophylaxis of Plague: Recommendations for Naturally Acquired Infections and Bioterrorism Response. — Nelson CA, Meaney-Delman D, Fleck-Derderian S, et al. MMWR. Recommendations and Reports : Morbidity and Mortality Weekly Report. Recommendations and Reports. 2021.
10. Intervention to Stop Transmission of Imported Pneumonic Plague - Uganda, 2019. — Apangu T, Acayo S, Atiku LA, et al. MMWR. Morbidity and Mortality Weekly Report. 2020.